Cancer Cell Biology group at the University of Helsinki is seeking outstanding candidates for postdoctoral researcher


The Faculty of Medicine promotes scientific research of a high standard and is responsible for providing research-based undergraduate and postgraduate education in medicine, dentistry, psychology and logopedics, as well as for the English-language Master’s Programme in Translational Medicine. In addition to its teaching and research activities, the Faculty serves as a significant expert organisation in the healthcare sector and contributes to the discourse on ethics in the field. In terms of research, the Faculty aims for a place among the best medical faculties in the world, while consolidating and strengthening its status as a top-level institution of medical education.

Together with the Helsinki University Hospital (HUS) and the Helsinki Institute of Life Sciences (HiLIFE), the Faculty of Medicine, University of Helsinki, constitutes the Academic Medical Center Helsinki (AMCH). This medical center has been very successful in international comparisons, ranking among the top 10 medical campuses in Europe and among the top 50 globally.

Research Programs Unit of the Faculty of Medicine is a top-quality research environment. Unit’s nine research programs comprises groups that integrate clinical, translational and biomedical research.

Cancer Cell Biology group led by Professor Päivi Ojala (https://www.helsinki.fi/en/researchgroups/cancer-cell-biology) at the Translational Cancer Medicine Research Program (CAN-PRO), Faculty of Medicine, University of Helsinki, is seeking outstanding candidates for 


The open positions are in the fields of cancer cell biology and/or virus-host interactions in a project funded by Academy of Finland.

Our research is focused to study the role of lymphatic endothelium in the tumor microenvironment and cancer metastasis. We are interested in the changes in the tumorigenic properties of the cancer cells upon contact with the lymphatic endothelium, (Pekkonen et al, eLife 2018; PMID:29712618) and also in the changes induced in the lymphatics by the tumor cells. In the virus-host interaction studies we are using Kaposi sarcoma herpesvirus (KSHV), an oncogenic human gamma-2 herpesvirus, as a model system to study cancer development and progression (Gramolelli et al, Sci Rep 2018; PMID:29934628). Ultimately, our studies aim to provide mechanistic insights into both improving existing clinical regimens and in identifying novels targets for therapeutic intervention.

We are looking for highly motivated post-doctoral fellows who have successfully completed a PhD in a field relevant to the molecular and cellular biology of cancer and/or virology and published at least one peer-reviewed article in a Pubmed-indexed journal. Experience in mammalian cell culture, cell and molecular biology, as well as microscopy techniques are required. Candidates with demonstrated skills and prior experience in the analysis of NGS datasets and/or mouse tumor models as well as proven track record in terms of publications will be given preference.

Initial contract of employment will be done until the end of 2020 and starting as soon as possible. The contract of employment includes a probationary period of 6 months. Salary will be based on the Universities salary scheme for teaching and research personnel composed of both task specific and personal performance components. 

The application should be in form of a single-pdf containing a one-page cover letter describing your areas of expertise and motivation for the position, recent CV with a publication list, and names and contact information of two to three references.

The application, together with the required attachments, must be submitted through the University of Helsinki electronic recruitment system by clicking on Apply for job. Internal applicants (i.e., current employees of the University of Helsinki) must submit their applications through the SAP HR portal.

Application at https://www.helsinki.fi/fi/avoimet-tyopaikat/postdoctoral-researcher . Apply at latest 10.04.2019.

Further information is available from Professor Päivi Ojala: paivi.ojala(at)helsinki.fi.